New hope for advanced cancer? JMT106 injection enters first human trial
NCT ID NCT07275073
First seen Jan 04, 2026 · Last updated Jun 22, 2026 · Updated 23 times
Summary
This early-stage trial tests a new drug called JMT106 in 200 people with advanced solid tumors, including lung and liver cancers, who have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug shows any sign of shrinking tumors. It is a first-in-human study, so results are very preliminary.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affilicated Hospital,Zhejiang University School of Medicine
RECRUITINGZhejiang, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
JMT106 injection
What this could lead to
If it works, this could point toward a new treatment option for people with advanced solid tumors who have run out of standard therapies.
What could go wrong
This is a very early Phase 1 trial with only 200 participants, so it is not yet known if JMT106 is safe or effective. Side effects may occur, and the drug may not shrink tumors.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.